Sarepta Therapeutics Inc (SRPT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sarepta Therapeutics Inc (SRPT) has a cash flow conversion efficiency ratio of -0.011x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-14.59 Million) by net assets ($1.32 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Sarepta Therapeutics Inc - Cash Flow Conversion Efficiency Trend (1995–2024)
This chart illustrates how Sarepta Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read SRPT current and long-term liabilities for a breakdown of total debt and financial obligations.
Sarepta Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sarepta Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
North Electro-Optic Co Ltd
SHG:600184
|
-0.036x |
|
National Vision Holdings Inc
NASDAQ:EYE
|
0.054x |
|
Shenzhen Ysstech Info-Tech Co Ltd
SHE:300377
|
-0.088x |
|
Marriot Vacations Worldwide
NYSE:VAC
|
0.025x |
|
Ningbo Yongxin Optics Co Ltd
SHG:603297
|
0.026x |
|
Zhejiang Jingxin Pharmaceutical Co Ltd
SHE:002020
|
0.040x |
|
Fsilon Furnishing and Construction Materials Corp
SHG:605318
|
0.036x |
|
Mesoblast Limited
F:LWB
|
-0.027x |
Annual Cash Flow Conversion Efficiency for Sarepta Therapeutics Inc (1995–2024)
The table below shows the annual cash flow conversion efficiency of Sarepta Therapeutics Inc from 1995 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Sarepta Therapeutics Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.53 Billion | $-205.79 Million | -0.135x | +76.90% |
| 2023-12-31 | $859.34 Million | $-500.99 Million | -0.583x | +31.02% |
| 2022-12-31 | $384.95 Million | $-325.35 Million | -0.845x | -76.98% |
| 2021-12-31 | $928.01 Million | $-443.17 Million | -0.478x | -438.51% |
| 2020-12-31 | $761.76 Million | $107.47 Million | 0.141x | +125.29% |
| 2019-12-31 | $818.19 Million | $-456.46 Million | -0.558x | -48.18% |
| 2018-12-31 | $1.03 Billion | $-388.66 Million | -0.377x | -28.08% |
| 2017-12-31 | $789.22 Million | $-232.00 Million | -0.294x | +59.74% |
| 2016-12-31 | $336.69 Million | $-245.82 Million | -0.730x | +7.02% |
| 2015-12-31 | $190.35 Million | $-149.47 Million | -0.785x | -51.29% |
| 2014-12-31 | $247.65 Million | $-128.54 Million | -0.519x | -98.31% |
| 2013-12-31 | $247.19 Million | $-64.69 Million | -0.262x | -9.01% |
| 2012-12-31 | $123.68 Million | $-29.69 Million | -0.240x | +68.55% |
| 2011-12-31 | $31.02 Million | $-23.68 Million | -0.763x | -114.14% |
| 2010-12-31 | $-2.82 Million | $-15.21 Million | 5.399x | +1549.76% |
| 2009-12-31 | $23.63 Million | $-8.80 Million | -0.372x | +52.52% |
| 2008-12-31 | $15.73 Million | $-12.34 Million | -0.784x | +16.15% |
| 2007-12-31 | $26.38 Million | $-24.68 Million | -0.935x | -71.13% |
| 2006-12-31 | $37.71 Million | $-20.61 Million | -0.547x | -99.95% |
| 2005-12-31 | $53.66 Million | $-14.67 Million | -0.273x | +69.80% |
| 2004-12-31 | $26.27 Million | $-23.78 Million | -0.905x | -124.74% |
| 2003-12-31 | $43.39 Million | $-17.48 Million | -0.403x | +53.32% |
| 2002-12-31 | $23.48 Million | $-20.26 Million | -0.863x | -105.49% |
| 2001-12-31 | $30.53 Million | $-12.82 Million | -0.420x | -53.48% |
| 2000-12-31 | $33.37 Million | $-9.13 Million | -0.274x | +57.16% |
| 1999-12-31 | $11.90 Million | $-7.60 Million | -0.639x | +14.21% |
| 1998-12-31 | $9.00 Million | $-6.70 Million | -0.744x | -354.11% |
| 1997-12-31 | $18.30 Million | $-3.00 Million | -0.164x | +91.80% |
| 1996-12-31 | $800.00K | $-1.60 Million | -2.000x | -124.72% |
| 1995-12-31 | $2.00 Million | $-1.78 Million | -0.890x | -- |
About Sarepta Therapeutics Inc
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exo… Read more